Is CBD a drug? What French law and the WHO say

The question "is CBD a drug?" bundles several. The word can refer to a narcotic banned by law, to a substance that changes how the brain works, or to a product that creates dependence. For CBD, the answer differs in each case.

The third row matters most. Cannabis is a narcotic because of the high, which THC produces; CBD, the plant's other major cannabinoid, produces no high.

French law treats as a narcotic any substance entered on an official list. Article R5132-86 of the Public Health Code bans the production, sale and use of cannabis, its plant, its resin and "tetrahydrocannabinols, natural or synthetic". Tetrahydrocannabinols also appear in Annex IV of the order of 22 February 1990, which sets the narcotics list. None of these texts names cannabidiol.

Hemp, the source of CBD, is governed by a separate text. The order of 30 December 2021 allows the cultivation, import, export and industrial and commercial use of Cannabis sativa L. varieties listed in the official catalogues whose Δ⁹-THC content does not exceed 0.30%. On 29 December 2022, the Council of State struck down the ban on selling raw flowers and leaves contained in that order. Our article on the legal THC level explains where the threshold comes from.

The threshold cuts both ways. At 0.25% THC, a hemp flower is a legal product; at 0.50%, the same flower is cannabis under criminal law. Using it then carries one year in prison and a €3,750 fine, or, since 20 August 2026, a €500 fixed fine. What tips the product over is its THC level, whatever its CBD content.

Kanavape was an electronic cigarette filled with CBD oil. Its CBD was extracted in the Czech Republic from whole hemp plants, flowers included, and packaged in France. At the time only hemp fibre and seeds could be sold, so the company's two managers were convicted in Marseille. The Aix-en-Provence court of appeal then referred the question to the Court of Justice of the European Union.

In its ruling of 19 November 2020 (case C-663/18), the Court observes that the UN Convention on Psychotropic Substances does not mention CBD. Read literally, the Single Convention on Narcotic Drugs could cover it as a cannabis extract. That reading would go against the purpose of the text, which is to protect health. The Court concludes that, on current knowledge, CBD "does not appear to have any psychotropic effect or any harmful effect on human health", so it cannot be considered a narcotic.

Member states keep some room under the ruling. They may still restrict CBD on public health grounds, if the measure is proportionate and supported by scientific data. The French aftermath is traced in our article on Kanavape.

In June 2018, the WHO Expert Committee on Drug Dependence reviewed cannabidiol. According to its critical review, CBD shows no effects in humans that point to any potential for abuse or dependence. The committee found no published case of abuse of or dependence on pure CBD, and no related public health problem. It therefore recommended not placing pure CBD under international control.

Two controlled trials agree. In 2017, a US team gave 31 frequent cannabis smokers oral CBD at 200, 400 or 800 mg, against a placebo and cannabis at 5.3-5.8% THC. Cannabis produced the effects users seek, while CBD matched placebo on every measure. The Epidyolex summary of product characteristics cites a study in recreational drug users. Set against dronabinol (synthetic THC) and alprazolam, an anti-anxiety drug, cannabidiol has low abuse potential.

An absence of dependence still leaves effects. At the medicine's doses, 10 to 25 mg per kilo per day, the same document reports drowsiness in 23% of treated patients, reduced appetite in 21% and diarrhoea in 20%. The liver enzymes that break down CBD also process many medicines, which explains its interactions with some treatments. Our article on CBD side effects reviews these data dose by dose.

MILDECA, the interministerial mission against drugs, puts the distinction in two sentences: CBD "does not cause dependence, unlike THC", and it has "psychoactive effects, in that it acts on the brain". Psychoactive means acting on the central nervous system, as caffeine also does. In everyday use, psychotropic describes a substance that alters perception, judgement or coordination. That is the cannabis high, and CBD does not produce it.

Receptors account for the difference. THC activates the brain's CB1 receptor directly, and that triggers the high; CBD does not activate it in this way. For the mechanisms, read does CBD get you high?.

A product labelled "CBD" contains more than CBD. Full-spectrum flowers, resins and oils also carry THC, up to 0.30%. Even in small amounts that THC is a narcotic, and it is what tests look for.

For drivers, article L235-1 of the Highway Code punishes driving after drug use with 3 years in prison and a €9,000 fine, and sets no minimum threshold. The Court of Cassation ruled on 21 June 2023 that the legality of the product bought makes no difference to the offence. Thresholds and detection times are explained in the guide CBD and saliva tests.

Semi-synthetic cannabinoids sold next to CBD are a second trap. The ANSM classified HHC as a narcotic from 13 June 2023, and H4CBD, THCP and other derivatives from 3 June 2024. Any product containing them is a narcotic, even under a "CBD" label. You can follow their history in our HHC timeline.